Re: Advair? Thanks Torsten

[Guest guest]

Thanks Torsten

Interesting reading. Hopefully after she gets cleared out these

results will for us. since she started on it Jess has coughed up

mucus plugs like crazy. and I guess opened air way that have been

blocked for a long time because her cough has worsened and is now

running a temp and is getting real tired. she has started taking

Zithromax for 10 days and then follows with a maintenence schedule.

We are getting tired of this. couging throught e night and couhging

in the morning until she throws up and wers herself out. Sorry I

didn't mean to go off on my tangent I just had to vent.

Dana 12

> Hi Dana,

>

> I have no clue about Advair, but thought you may find the abstract

> interesting.

>

> Peace

> Torsten, dad of Fiona 5wcf

> e-mail: torstenkrafft@w...

>

> Subject: Article on Advair

>

> CHEST: Cost-Effectiveness Analysis Suggests Advair

> (Fluticasone/Salmeterol) Associated with Lower Costs than Budesonide

> Plus Formoterol "

> By Peggy Peck Special to DG News SAN DIEGO, CA -- November 5, 2002 -

- A

> cost-effectiveness analysis found that the asthma management

combination

> fluticasone Advair =AE (fluticasone/salmeterol) is more cost

effective

> than budesonide plus formoterol. Laureen Rance, MD of

GlaxoKline,

> Canada, and colleagues used data collected from a Norwegian

prospective

> multi-center study comparing fluticasone/salmeterol (FS) and

budesonide

> (BUD)plus formoterol (FORM) to model projected Canadian costs. The

> European multicenter, 12-week, randomised, controlled trial enrolled

> adult asthmatics who were symptomatic on 1000 to 1600 =B5g inhaled

> beclomethasone (or equivalent). The researchers randomised 212

patients

> to FS at doses of 250/50 =B5g bid and 216 patients to BUD 800 =B5g

bid

> plus FORM 12 =B5g bid. The researchers also collected non-protocol

> mandated asthma-related healthcare utilisation data during the

trial.

> Canadian costs were applied to the secondary effectiveness measures:

> symptom-free nights, symptom-free days, episode-free days, and weeks

> with greater than 5 percent improvement from baseline in morning

PEF.

> The primary objective of showing non-inferiority was met as the

primary

> outcome morning PEF, as F/S produced similar results to BUD+FORM

> (p=3D0.593). Patients in the F/S arm had significantly more symptom-

free

> nights (p<0.05) and significantly fewer exacerbations than those in

the

> BUD+FORM arm. The F/S group had lower total daily asthma management

> costs ($3.60 per patient) than the BUD+FORM group ($4.96 per

patient).

> The BUD+FORM group had a higher number of asthma-related

> hospitalisations, which resulted in higher mean treatment costs in

that

> arm, she said. The study was funded by GlaxoKline, Canada.